![PD-1/PD-L1 Blockade Bioassay](/storage/FBB87434D7CD20401C19AEBEFE5DF4630128C83A8E41F4F073CC2B6C0F3D9A2F/7de0f16ecf3442ce9d3c6e245b44aea7/840-840-0-png.Png/media/314e13d0dc7b45e58721193c4395c69e/J1250_PD-1%20PD-L1%20Blockade%20Bioassay_2.png)
![PD-1/PD-L1 Blockade Bioassay](/storage/2C0368D2E15C5A935E0433D19C1A18EDFA214F8C70E4FCE4BDA82D80C7346DF6/6c6d342a4f134668966db30a49c4f586/png/media/2e9c698ffa5b4930876cb80a3dfa09b6/J1250.png)
![PD-1/PD-L1 Blockade Bioassay, 5X](/storage/D3DE6F130400BC5CD4B3D55F5D7253E38667B89446F740DAC8973E20AD606DCA/c5d52b3b17fe44fa8eacaa5c6d582ce3/840-840-0-png.Png/media/84c3392df2974e09a8a1999405a6235f/J1255_PD-1%20PD-L1%20Blockade%20Bioassay%205X_2.png)
![PD-1/PD-L1 Blockade Bioassay, 5X](/storage/2C65805AC05E235C955D14ADF6D3F7569B6E9B2333D08530BB6D8F58A250613D/ed55dbbdd54e416e81b6762f6779f1d4/png/media/46b8c17bc15c4101ab4ef968b511beaf/J1255.png)
![PD-L1 Negative Cells](/storage/5DABBD0F9B529A5F486C83600239D7EC9E595CD3E10CDCE9CCCC67498DAE5329/26910b8933ab4e909b86b24390c50aac/840-840-0-png.Png/media/30f9dc302eab4df9b10732bcc8fb516c/J1191_PD-L1%20Negative%20Cells_2.png)
![PD-L1 Negative Cells](/storage/89A686149EEC8216E326448C3726B83574B3FAB650BAA23785183C072A4ABA7F/4de5be2d8e324e55bec6faaf7d16e266/png/media/a1e97a0d40be4775bfa0db143f26ea73/J1191.png)
![Control Ab, Anti-PD-1](/storage/32CD2D6DC16D66C9B8E79E59A61912D317DE110FAE39062419433DBC776D9652/b69aa123f3ba4f5fbf9c4d7287e6b4a4/840-840-0-png.Png/media/8703a0e5db9b4c649dc2a4ffa3d3dfc6/J1201_Control%20Ab%20Anti-PD-1_2.png)
![Control Ab, Anti-PD-1](/storage/9E1443DBBCA10DD69E533F44EBCAF0544EEC020E7F57CDA3BDE5C9620A457E69/a5074508385a499ea7188fb9bf9f6a9a/840-560-0-png.Png/media/0619be01c3324ee7865c0672cbd11c40/J1201_Control%20Ab%2C%20Anti-PD-1.png)
![Control Ab, Anti-PD-1](/storage/53B90CDFC2110CC8D662953175DAB728A44AC0F8F988D925497B7FA833B6774D/393c9539b778476f81757e7d3d5789c7/840-840-0-png.Png/media/fde73ff550164df884d7e97c96f9b9e7/J1201_Control%20Ab%2C%20Anti-PD-2.png)
![Control Ab, Anti-PD-1](/storage/A15D155ADBC0946B7EC325840AEA367E2359EF65ECEF5B35C9EA8508B0FBBACA/741b24ddc55241c4bb598acb265983c3/png/media/61fc1d0ebb034af1a003cb05d8b26988/J1201.png)
![PD-1/PD-L1 Blockade Bioassay, Propagation Model](/storage/DD732A8E42B0EA5CC1F6FDCBBDD746D958EDF8D5CAE8BFD1BE7350EC9F59C31A/96b4e36f9a01488184d2ca6dc771644e/png/media/168298bfe8674715972933f33223a4a6/J1252.png)
![PD-L1 Negative Cells 5X](/storage/397BBCA5EEDC96D6420EBCD8DAF8A3DFFC1C777AF5E7F1F54553352AC22B00EA/1152aabd1cbe47af803bb5c2d69e2ff7/840-840-0-png.Png/media/612976cf37aa4cc2ba9351e855f0e1bd/J1195_PD-L1%20Negative%20Cells_2.png)
![PD-L1 Negative Cells 5X](/storage/E1B94F04073579D2CF7475A422FD9107B9DEF5287EE0F04DE3862FAF5B8E0603/7fbb2f63dffd4bddb0a2cd5ffeef703a/png/media/368dadbb75f649588f6366f9af30178a/J1195.png)
Promega
Control Ab, Anti-PD-1
PD-1/PD-L1 blokkeringsbioassayet er en biologisk relevant MOA-basert prøve som kan brukes til å måle potens og stabilitet av antistoffer og andre biologiske midler designet for å blokkere PD-1/PD-L1-interaksjonen. Assayet består av to genetisk konstruerte celletyper: PD-1 Effektorceller: Jurkat T-celler som stabilt uttrykker humant PD-1 og NFAT-indusert luciferase; PD-L1 aAPC/CHO-K1-celler: CHO-K1-celler som stabilt uttrykker humant PD-L1 og en celleoverflateprotein designet for å aktivere kognate TCR-er på en antigen-uavhengig måte. Når de to celletypene dyrkes sammen, hemmer PD-1/PD-L1-interaksjonen TCR-signalering og NFAT-mediert luciferaseaktivitet. Tilsetning av et antistoff som blokkerer enten PD-1 eller PD-L1 frigjør den inhiberende signalet og resulterer i TCR-signalering og NFAT-mediert luciferaseaktivitet. Produktpakkeformat og relaterte produkter: Pakker er tilgjengelige i størrelsene 1X og 5X. Kontroll Ab, Anti-PD-1 er tilgjengelig separat. PD-L1 negative celler er tilgjengelige separat.
Denne teksten er oversatt ved hjelp av AI og kan inneholde unøyaktigheter.